ITCC-090 Ramucirumab RSS
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma
Promotor Name : Eli Lilly and Company
Investigator Name :
Trial registered on clinicaltrial.gov : NCT04145700
